Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression.

Fan Y, Limprasert P, Murray IV, Smith AC, Lee VM, Trojanowski JQ, Sopher BL, La Spada AR.

Hum Mol Genet. 2006 Oct 15;15(20):3002-11.

2.

Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?

Fujita M, Sekigawa A, Sekiyama K, Sugama S, Hashimoto M.

J Neurol. 2009 Aug;256 Suppl 3:286-92. doi: 10.1007/s00415-009-5246-8. Review.

PMID:
19711118
3.
4.

Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?

Olanow CW, Brundin P.

Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373. Review.

PMID:
23390095
5.

Development of new treatments for Parkinson's disease in transgenic animal models: a role for beta-synuclein.

Masliah E, Hashimoto M.

Neurotoxicology. 2002 Oct;23(4-5):461-8. Review.

PMID:
12428718
6.

Controlling the mass action of alpha-synuclein in Parkinson's disease.

Kim C, Lee SJ.

J Neurochem. 2008 Oct;107(2):303-16. doi: 10.1111/j.1471-4159.2008.05612.x. Review.

7.

Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?

Windisch M, Wolf HJ, Hutter-Paier B, Hofmeister A, Wronski R.

Curr Alzheimer Res. 2007 Sep;4(4):446-57. Review.

PMID:
17908049
8.

Mechanisms and models of alpha-synuclein-related neurodegeneration.

Springer W, Kahle PJ.

Curr Neurol Neurosci Rep. 2006 Sep;6(5):432-6. Review.

PMID:
16928354
9.

Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease.

van Rooijen BD, Claessens MM, Subramaniam V.

Curr Protein Pept Sci. 2010 Aug;11(5):334-42. Review.

PMID:
20423294
10.

Synucleins and their relationship to Parkinson's disease.

von Bohlen Und Halbach O.

Cell Tissue Res. 2004 Oct;318(1):163-74. Review.

PMID:
15503152
11.

Alpha-synuclein aggregation and neurodegenerative diseases.

Ma QL, Chan P, Yoshii M, Uéda K.

J Alzheimers Dis. 2003 Apr;5(2):139-48. Review.

PMID:
12719631
12.
13.

Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.

Volles MJ, Lansbury PT Jr.

Biochemistry. 2003 Jul 8;42(26):7871-8. Review.

PMID:
12834338
15.

[Role of genetics in the etiology of synucleinopathies].

Elcoroaristizabal Martín X, Gómez Busto F, González Fernández MC, de Pancorbo MM.

Rev Esp Geriatr Gerontol. 2011 Oct;46 Suppl 1:3-11. doi: 10.1016/j.regg.2011.10.002. Review. Spanish.

PMID:
22152908
16.

Alpha-synuclein and transgenic mouse models.

Fernagut PO, Chesselet MF.

Neurobiol Dis. 2004 Nov;17(2):123-30. Review.

PMID:
15474350
17.

Alpha-synuclein, Parkinson's disease, and Alzheimer's disease.

Kim S, Seo JH, Suh YH.

Parkinsonism Relat Disord. 2004 May;10 Suppl 1:S9-13. Review.

PMID:
15109581
18.

Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy.

Paleologou KE, Irvine GB, El-Agnaf OM.

Biochem Soc Trans. 2005 Nov;33(Pt 5):1106-10. Review.

PMID:
16246056
19.

The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.

Wakabayashi K, Tanji K, Mori F, Takahashi H.

Neuropathology. 2007 Oct;27(5):494-506. Review.

PMID:
18018486
20.

Overexpression of alpha-synuclein following methamphetamine: is it good or bad?

Mauceli G, Busceti CI, Pellegrini A, Soldani P, Lenzi P, Paparelli A, Fornai F.

Ann N Y Acad Sci. 2006 Aug;1074:191-7. Review.

PMID:
17105917
Items per page

Supplemental Content

Support Center